Menu
OUR SCIENCE
A TARGETED APPROACH FOR TREATING HEMATOLOGICAL CANCERS AND BEYOND
Kurome Therapeutics is a late preclinical stage company that is developing a series of potent and differentiated IRAK1/4, panFLT3 inhibitors. Our robust preclinical data package includes:
-
Broad range of efficacy in MDS and AML patient-derived cell lines
-
Synergy with Venclexta® (Venetoclax) to improve Venclexta® potency
-
Increased overall survival in cell line and patient-derived xenograft models, well beyond that of existing IRAK4 inhibitors and FLT3 inhibitors
-
Maintenance of complete efficacy even in settings of adaptive resistance to FLT3 inhibitors and in settings of FLT3 mutations
-
Development of IRAK1/4 gene signature
The IRAK1/4 Signaling Complex Lies At A Critical Signaling Node That Drives Cancer Cell Survival Through Multiple Mechanisms
-
The IRAK1/4 Signaling Complex Lies At A Critical Signaling Node That Drives Cancer Cell Survival Through Multiple Mechanisms
-
Over-Activation Of This Pathway In Cancer Cells Acts As An Oncogene-Like Driver That Mediates Cancer Cell Growth And/Or Survival
-
This Signaling Node Is Also A Key Molecular Hub For Modulation Of Stress Response Pathways Following Cancer Therapies That Mediate Resistance And Contribute To Relapse
-
Inhibition Of The IRAK1/4 Signaling Complex Subverts Cancer’s Ability To Mount The Stress Response, And Ablates The Dependency Of The Cancer Cell On The Over-Activated Immune Signaling Pathways
OUR PIPELINE
CHECK OUT OUR LATEST NEWS
Check out our news page for the latest information on technology and more!